Abstract
Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, avelumab and durvalumab. We identified 3 prospective studies, 17 retrospective studies and 4 case series reporting 363 patients in total. Combined data from all three prospective studies provide a prevalence rate of 6.13%. Most patients were males (59.68%) and the vast majority (73%) were on programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. Most studies report a median time of ≤ 12 weeks from first ICI administration to symptom onset. The main clinical phenotypes reported were: (a) inflammatory arthritis (57.57%), (b) myositis (14.04%) and (c) polymyalgia rheumatica (PMR) (12.12%). A total of 256 patients required steroids (70.52%) and 67 patients (18.45%) were treated with DMARDs. Positive auto-antibodies and family history of any autoimmune disease were present in 18.48% and 19.04% of cases, respectively. Only a few patients (19%) had to discontinue treatment due to musculoskeletal Ir-AE. Two prospective studies show that significantly more patients with musculoskeletal Ir-AE exhibit a favorable oncologic response compared to patients not exhibiting such manifestations whereas retrospective studies show that 77.22% of patients with musculoskeletal Ir-AE have a good tumor response. One out of 15 patients treated with ICI will develop musculoskeletal Ir-AE; in most cases the severity of these manifestations is mild/moderate and usually ICI may be continued. Rheumatologists should familiarize with this new clinical entity and develop relevant therapeutic algorithms.
Similar content being viewed by others
References
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
Farhood B, Najafi M, Mortezaee K (2019) CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509–8521
Tivol EA, Borriello F, Nicola Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547
Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141–151
Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29:71–83
Park Y-J, Kuen D-S, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:109
Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang Y-H (2018) Immune checkpoint inhibitors in cancer therapy. J Biomed Res 32:317–326
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168
Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60
Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Haralabos Kalofonos S-NL (2020) MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations. Myofasciitis is the prominent imaging finding. Rheumatology (Oxford) 59:1041–1050
Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C et al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393–398
Narváez J, Nolla JM, García X, del Muro J, Lluch JAN, Domingo-Domenech E et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17:1040–1045
Kostine M, Truchetet M-E, Schaeverbeke T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology 58:vii68–vii74
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H et al (2020) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217139
Daoussis D, Melissaropoulos K, Dimitroulas T, Andreadis H, Christopoulou A, Douganiotis G et al (2020) Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterr J Rheumatol 31:239
Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468–475
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44
Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y et al (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284–289
Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50
Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B et al (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747–1750
Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP et al (2019) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48:1127–1132
Smith MH, Bass AR (2019) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res 71:362–366
Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME (2019) Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 48:736–740
Lee J, Graham A, Sion A (2019) Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract 25:1867–1872
Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J et al (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553–557
Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF et al (2018) Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175–182
Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B et al (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88–102
Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225
Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23
Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412
Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M et al (2018) Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4(2):e000714. https://doi.org/10.1136/rmdopen-2018-000714
Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC (2019) Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 22:297–302
Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL (2018) Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 47:907–910
Goldstein BL, Gedmintas L, Todd DJ (2014) Concise communication. Arthritis Rheumatol 66:768–769
Chan MMK, Kefford RF, Carlino M, Clements A, Manoliosz N (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma case presentation case 1. J Immunother 38:37–39
Garel B, Kramkimel N, Trouvin AP, Frantz C, Dupin N (2017) Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Jt Bone Spine 84:233–234
Weinstock C, Singh H, Maher VE, Kim G, Pazdur R (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. J Clin Oncol 35:3018–3018
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis Rheumatol 71:2100–2111
Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68:917–926
Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234–240
Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24–32
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21–29
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376
Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905–1912
Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G et al (2016) The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol 27:1174–1177
Ruiz-Bañobre J, Pérez-Pampín E, García-González J, Gómez-Caamaño A, Barón-Duarte FJ, López-López R et al (2017) Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer 108:217–221
Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 14(2):35
Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M et al (2019) Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38:1513–1519
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Rottapel R et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595
Liu Y, Jaquith JM, Mccarthy-Fruin K, Zhu X, Zhou X, Li Y et al (2020) Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05162-9
Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586
Nguyen T, Maria ATJ, Ladhari C, Palassin P, Quantin X, Lesage C et al (2020) Rheumatic disorders associated with immune checkpoint inhibitors: What about myositis? An analysis of the WHO’s adverse drug reactions database. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217018
Matas-García A, Milisenda JC, Selva-O’Callaghan A, Prieto-González S, Padrosa J, Cabrera C et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19:102455
Martin de Fremont G, Belkhir R, Henry J, Voisin AL, Lambotte O, Besson FL et al (2020) Features of polymyalgia rheumatic-like syndrome after immune checkpoint inhibitor therapy. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217225
Van Der Geest KSM, Sandovici M, Rutgers A, Hiltermann TJN, Oosting SF, Slart RHJA et al (2020) Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217381
Murray-Brown W, Wilsdon TD, Weedon H, Proudman S, Sukumaran S, Klebe S et al (2020) Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother cancer. https://doi.org/10.1136/jitc-2019-000281
Moura CA, Moura CG (2020) Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217605
Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J et al (2019) Checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79:332–338
Funding
This study was not funded by any source.
Author information
Authors and Affiliations
Contributions
FA performed the literature search, extracted data from the retrieved articles, analyzed the data and assisted in manuscript drafting. DB, TD and LS assisted in the design of the study, data analysis and manuscript drafting. DD conceived the idea and designed the study, extracted data from the retrieved articles, analyzed the data and drafted the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Angelopoulou, F., Bogdanos, D., Dimitroulas, T. et al. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol Int 41, 33–42 (2021). https://doi.org/10.1007/s00296-020-04665-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-020-04665-7